Graham Capital Management L.P. Sells 126,536 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Graham Capital Management L.P. decreased its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 70.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 53,069 shares of the medical technology company's stock after selling 126,536 shares during the period. Graham Capital Management L.P.'s holdings in Alphatec were worth $487,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in ATEC. Vanguard Group Inc. lifted its holdings in shares of Alphatec by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,968,980 shares of the medical technology company's stock worth $54,795,000 after purchasing an additional 47,797 shares during the last quarter. American Century Companies Inc. lifted its stake in Alphatec by 36.5% in the fourth quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company's stock valued at $45,800,000 after buying an additional 1,334,780 shares during the last quarter. Geode Capital Management LLC lifted its stake in Alphatec by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 2,387,162 shares of the medical technology company's stock valued at $21,919,000 after buying an additional 24,283 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Alphatec by 139.2% during the fourth quarter. Marshall Wace LLP now owns 1,773,246 shares of the medical technology company's stock valued at $16,278,000 after acquiring an additional 1,032,070 shares during the period. Finally, Penn Capital Management Company LLC grew its position in shares of Alphatec by 17.5% during the fourth quarter. Penn Capital Management Company LLC now owns 1,535,182 shares of the medical technology company's stock worth $14,093,000 after acquiring an additional 228,933 shares during the last quarter. Institutional investors own 66.35% of the company's stock.

Alphatec Price Performance

Shares of ATEC traded up $0.07 during mid-day trading on Monday, hitting $13.03. The company's stock had a trading volume of 1,277,526 shares, compared to its average volume of 2,035,399. The firm has a 50-day moving average price of $10.73 and a 200 day moving average price of $10.40. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -10.18 and a beta of 1.06. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $13.08.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The business had revenue of $169.18 million during the quarter, compared to analyst estimates of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business's revenue for the quarter was up 22.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.34) EPS. On average, research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Insider Activity

In related news, CEO Patrick Miles sold 32,393 shares of the company's stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $10.89, for a total transaction of $352,759.77. Following the completion of the sale, the chief executive officer now directly owns 5,940,391 shares of the company's stock, valued at approximately $64,690,857.99. This represents a 0.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Scott Lish sold 12,000 shares of the firm's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $12.12, for a total transaction of $145,440.00. Following the completion of the transaction, the chief operating officer now owns 826,251 shares in the company, valued at $10,014,162.12. The trade was a 1.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 126,945 shares of company stock worth $1,416,352 over the last quarter. Corporate insiders own 20.90% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on ATEC shares. Needham & Company LLC reissued a "buy" rating and set a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd. Barclays boosted their price objective on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 22nd. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research report on Monday, April 14th. Piper Sandler reiterated an "overweight" rating and set a $15.00 price objective (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Finally, StockNews.com upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $17.89.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.